Key facts
- It has raised $63.0M; the latest was Early Stage VC ($14.3M) in Jan 2026.
- Notable investors include Legend Capital, Lapam Capital, SDIC Unity Capital, Shenzhen Yifeng Investment Management Enterprise, Hangzhou Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Alioth Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Alioth Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alioth Biotech
Developer of filtration-based pharmaceutical processing systems intended for separation and purification in drug manufacturing. The company offers depth filtration, sterile filtration for liquids and gases, prefiltration modules, membrane hardware, and laboratory validation services, enabling pharmaceutical manufacturers to meet regulatory compliance, enhance production safety, and optimize bioprocess workflows through integrated, GMP-compliant infrastructure and cross-border R&D capabilities.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 200
- Website
- aliothbio.com/
- Ownership
- Privately Held (backing)
Alioth Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alioth Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alioth Biotech in its N-PORT filings yet. We sweep new filings monthly.